Webinar 1 What can we learn from China about COVID-19?

COVID-19 may have started in China but its response has given us hope that the crisis can be controlled and slowed down. What can we learn from China's experience and how can investors adapt?

23 Mar 2020

China also gives us hope that the outbreak can be controlled and slowed down.

And hence this crisis too shall pass.

Geoffrey Wong, Head of Emerging Markets and Asia Pacific Equities told investors over a webinar recently.

He is joined by Hayden Briscoe, Head of Fixed Income, Asia Pacific, and Projit Chatterjee, Senior Investment Specialist, Emerging Markets and Asia Pacific Equities.

Subscribe now

Perspectives matter. Tune in to our insights.

  • The reaction to the outbreak has varied across countries as they have traded controlling the outbreak and fatalities on one side with the economic impact of the control measures on the other;
  • China and some other Asian countries have weighed more on the side of control – wisely it now seems – because as the outbreak has escalated globally, a significant near-term economic impact is inescapable;
  • However, China also gives us hope that the outbreak can be controlled and slowed down. And hence this crisis too shall pass;
  • And while markets have understandably reacted negatively, that should not make us ignore the structural trends in China and emerging markets, and how some of these are accelerating and creating long-term investment opportunities;
  • There is a compelling case for a dedicated strategic allocation to China - China Equity and Fixed Income offer very large hunting grounds for alpha and yield - and the world remains very underinvested in both.

COVID-19 in China: some signs that China's economy is returning to normal

New cases of coronavirus in China have tailed off sharply

The number of new coronavirus cases being reported per day in China has tailed off sharply through March. New reported cases spiked in mid-February - because of a change in how infected cases were defined - but have fallen rapidly since then.

Most of the new cases being reported in China in the past few days have come from Chinese citizens returning with the virus from overseas, but domestic cases have been down sharply.

The number of new cases being reported per day in China has tailed off sharply through March

New confirmed cases of Coronavirus in China (per day), Jan 23, 2020-Mar 18, 2020

Source: Johns Hopkins Coronavirus Resource Centre, CSSE, March 18th, 2020

Increasing economic activities in China

There have been upward trends in economic activity in China following Chinese New Year. Though yet to reach the same activity levels as last year, trends in traffic congestion and property sales offered some evidence that activity in China's economy is beginning to return to normal.

Short-and long-term impacts of COVID-19 in China

The immense precautions being taken will have a notable impact on global GDP. There is a growing consensus in the markets that there will be a global recession this year.

On the other hand, coordinated fiscal and monetary measures are underway which may have a countervailing impact on the global economy. In past global recessions, markets fell by as much as 50%, currently they are down about 25% so far. Although this does not at all necessarily imply that markets will fall to the 50% level, further downside from today is quite possible.

Other things will happen as well, stimulus is already happening, and there may be progress with a vaccine which may positively impact markets.

Markets will remain volatile but fundamental long-term trends in China and Asia remain intact, so the longer-term impact for investors over the next three-to-five years should be small.

Specifically, a series of trends are accelerating both in China and more widely in Asia which are part of ourinvestment strategies, including:

  • Ongoing consolidation within many industries in China as smaller firms struggle;
  • Shift from offline to online across business segments, especially after-school tutoring, financial services, and healthcare diagnosis;
  • Investment in R&D and innovation, driven by growing demand for automated solutions;
  • Shifts in supply chain; South-East Asia and India could benefit, plus reshoring back to US, Korea, Japan;

Impact on industries in EM

There are two key factors for this: firstly, market inefficiencies caused by the retail-driven investor base and, secondly, long-term fundamental trends that are driving the economy.

Trends like the shift to a service and consumption-driven economy, ongoing urbanization, premiumization, increasing R&D and innovation, and China's aging society, are all long-term fundamental trends that are creating winners and losers.

Despite the near term challenge from coronavirus, we remain confident in the fundamental, long-term changes playing out in China and emerging markets and our strategies are focused on quality companies associated with them.

In closing, we continue to remain cautious, with no major portfolio changes yet, but remain prepared to make portfolio changes at appropriate price points, especially by adding to positions in high-quality industry leaders.

Geoffrey Wong, Head of Emerging Markets and Asia Pacific Equities

Investing in China is not about beta investing but accessing active return and investors can find rich alpha opportunities in China's A-share market.


Coronavirus: the view from China's bond markets

The Chinese government has flooded the market with liquidity and drastically eased monetary policy.

Bloomberg, March 17, 2020

Key interest in China: SHIBOR and Loan Prime Rate (%), February 2018-February 2020

What hasn't been so widely reported is the extent to which the Chinese government has stepped in.

Effectively, they have lent directly into sectors and segments of the market and ruled out defaults in the market this year. This makes for a marked contrast to the rest of the world, and we have seen cases of spreads narrowing in Chinese markets.

Looking globally, China government bonds continue to offer some of the highest nominal yields in global markets today, and look particularly attractive in a world of increasingly negative yield.

Bloomberg, March 17, 2020

Nominal yields (%) on ten-year government bonds, March 17th, 2020

China's onshore markets remain relatively stable compared to other major markets globally, with volatility staying markedly below the US and Europe both historically and particularly during the recent bouts of market turmoil.

In this respect, China's fixed income markets remain a standout with relatively low correlation.

Hayden Briscoe, Head of Fixed Income, Asia Pacific


Q&A with Projit Chatterjee

Geoffrey Wong (GW): China has done well after the initial hiccups in Wuhan. A few factors are key: firstly, very strict social distancing and quarantine measures; secondly, widespread testing and contact tracing of people and, finally, very clear statements on the economic side that they will do 'whatever it takes' to stabilize the economy.

In sum, fast decisive action to keep infection rates low. The Chinese authorities have wanted to keep the number of peak infections lower than the number of ICU beds that they have. This factor is vital because patients kept in ICU facilities have a much higher chance of survival.

Hayden Briscoe (HB): To adapt and adapt quickly. I have recently been in London and was shocked to see how few people were taking the virus seriously. For example, I was only one of five people at Heathrow airport wearing a mask – a stark contrast to Hong Kong and China, where everyone is wearing them.

GW: The long-term outlook still is optimistic for certain companies and industries. In the short term, a global recession seems to be likely. The medium market reaction will be a complex mixture of very bad economic and earnings, ample stimulus and the wildcard of progress (or lack of) on a vaccine. We can look at the stock prices being served to us daily, with a view as to whether individual stocks are compelling value if held for the long term. This is what we do.

GW: We supplement official numbers with data from alternative datasets. We set up a team called QED that supports us in these alternative data analytical efforts. Examples that help track China activity include: air pollution data, traffic congestion, property transactions, airplane and train ticket sales. These help to verify official data.

GW: The boots are off the ground at the minute, but we have our ears to the ground - we have ramped up the number of daily management telephone calls. So we are keeping in very close contact with the companies and the conversations we are having with them focus on the impact they are seeing and feeling from coronavirus.

HB: We don't expect the economy to bounce back to 5%-6% any time soon. The thing to focus on now is not GDP, but what we call China's credit impulse – the growth rate of total credit in the economy as a percentage of total GDP. This is closely related to the outlook for the economy six-to-nine months ahead.

The credit impulse is turning positive, and we wouldn't be surprised to see it pick up markedly in the coming months. That's because the Chinese government has done an excellent job in driving cash into the real economy. Currently, overnight cash rates are very low at around 1.5%.

GW: Yes, Coronavirus has been a very good test of the standalone China thesis. If you look at how global markets have performed, they have been down around 25%, yet the China A-share market has been down around 3%. The A-share market has a very different investor base, which is dominated by domestic retail investors.

Though Stock Connect is growing in importance, domestic investors in China still have very few avenues to send their money abroad, so they are concentrated domestically. These investors are driven by different factors compared to investors in say the US or Europe, and so the correlation between the markets is low.

The domestic Chinese citizens are reassured by the decisiveness of their government at this time, and so China's markets have been relatively stable. So this lack of correlation between what's happening in China and the rest of the world is a very strong argument for why global investors should look at China A-shares as a separate asset class.

Not only is the active return there – and that’s of course the primary reason to be there – but the correlation is low. So you will actually lower your overall portfolio risk with a moderate amount of China A-shares in your global portfolio. So this strengthens the argument for China as a separate asset class.

HB: Since the 1980s our entire industry has been based on negative correlation between fixed income assets and risky assets. That anchor has been taken away now you get to zero, so you have to rethink your strategy, or find assets that replace it.

Unfortunately, as we go into this slowdown, people are missing out on income and they don't have a defensive bond in their portfolio. It is likely that investors will shift to Chinese bonds only after they realize this.

It takes a big call for a CIO to embrace the peer risk here and make a higher allocation to China. If you just follow the indexes, China is only 6% of the index, but it’s the second largest market in the world.

It is not big enough to move the needle if you leave your China allocation inside an index, so you have to make a strategic allocation. We're saying that's somewhere around 40% to China, 40% to Treasuries, and the rest to other smaller fixed income markets like UK, Australia, and New Zealand.

We'd also advise doing it on a fully hedged basis. So CIOs need to make bigger calls. For 30 years, managers left it up to the indexes, but we're saying now that investors have to pick the countries, and rethink their allocations.

HB: We are going into full lockdown in places like Taiwan and Hong Kong, with strict quarantine laws. There's going to be a slowdown, and that is positive for Chinese bonds, because it means more rate cuts, higher liquidity, and we will likely see a continued rally.

GW: Secondary effects will occur. We have to think now about how we use our risk budget. Markets have fallen about halfway, good quality stocks haven't quite fallen as much. From our portfolio action, we are still keeping dry powder to use for when all the bad news is out there. We have used some ammunition to buy into some selected stocks.

HB: As for market liquidity, it's perfectly fine in the government space or onshore. All the onshore credits are actually bid, so the credit spreads are actually contracting. Offshore is more challenging, perversely there is more liquidity in the high yield markets because the Chinese investors are looking for hard currency, USD-denominated Chinese issuers. Conditions are challenging in investment grade assets.

GW: Generally, we are still able to adjust our portfolios. Obviously when you are buying and selling the selling is slightly more difficult that the buying in this environment and spreads during the day can be fairly large. With the exception of the Philippines, we have had continuous trading in other markets, so markets are still functioning.

GW: On the wholesale side we have seen decent inflows YTD. On the institutional side we have had two fundings and one redemption in the last month. Net-net, investors seem to be looking at the current situation as an opportunity. Partly, that's because we have one of the top-performing products. Generally in Asia, there have been redemptions, but we haven't seen much of this so far.

HB: We have seen a lot of clients selling negative-yielding assets or EM debt and then switching into China fixed income for higher yields and more safety.

More insights

Singapore Retail Investors

PLEASE READ THESE TERMS AND CONDITIONS CAREFULLY BEFORE PROCEEDING. BY UTILIZING THE WEBSITE AND PAGES THEREOF LOCATED AT WWW.UBS.COM/AM-SG ("WEBSITE"), YOU ACKNOWLEDGE THAT YOU HAVE READ THESE TERMS AS WELL AS THE GLOBAL TERMS OF USE (collectively "TERMS") AND THAT YOU AGREE TO BE BOUND BY THEM. IF YOU DO NOT AGREE TO ALL OF THE TERMS OF THIS AGREEMENT, YOU ARE NOT AN AUTHORIZED USER OF THESE SERVICES AND YOU SHOULD NOT USE THIS WEBSITE.

This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2020 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

Reset